Research programme: cancer vaccines - SELECT Therapeutics
Latest Information Update: 01 Nov 2006
At a glance
- Originator SELECT Therapeutics (CEASED)
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Nov 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 10 Aug 2000 New profile